These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 9499040)

  • 1. Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage.
    Montefiori DC; Collman RG; Fouts TR; Zhou JY; Bilska M; Hoxie JA; Moore JP; Bolognesi DP
    J Virol; 1998 Mar; 72(3):1886-93. PubMed ID: 9499040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.
    Trkola A; Ketas T; Kewalramani VN; Endorf F; Binley JM; Katinger H; Robinson J; Littman DR; Moore JP
    J Virol; 1998 Mar; 72(3):1876-85. PubMed ID: 9499039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.
    Trkola A; Matthews J; Gordon C; Ketas T; Moore JP
    J Virol; 1999 Nov; 73(11):8966-74. PubMed ID: 10516002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of an unique CXCR4 epitope whose ligation inhibits infection by both CXCR4 and CCR5 tropic human immunodeficiency type-I viruses.
    Adachi T; Tanaka R; Kodama A; Saito M; Takahashi Y; Ansari AA; Tanaka Y
    Retrovirology; 2011 Oct; 8():84. PubMed ID: 22018245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1.
    Xiang J; George SL; Wünschmann S; Chang Q; Klinzman D; Stapleton JT
    Lancet; 2004 Jun; 363(9426):2040-6. PubMed ID: 15207954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection.
    Lehner T
    Trends Immunol; 2002 Jul; 23(7):347-51. PubMed ID: 12103354
    [No Abstract]   [Full Text] [Related]  

  • 7. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression.
    Xiao L; Rudolph DL; Owen SM; Spira TJ; Lal RB
    AIDS; 1998 Sep; 12(13):F137-43. PubMed ID: 9764773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.
    Scarlatti G; Tresoldi E; Björndal A; Fredriksson R; Colognesi C; Deng HK; Malnati MS; Plebani A; Siccardi AG; Littman DR; Fenyö EM; Lusso P
    Nat Med; 1997 Nov; 3(11):1259-65. PubMed ID: 9359702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro.
    Lopalco L; Barassi C; Pastori C; Longhi R; Burastero SE; Tambussi G; Mazzotta F; Lazzarin A; Clerici M; Siccardi AG
    J Immunol; 2000 Mar; 164(6):3426-33. PubMed ID: 10706739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.
    Cecilia D; KewalRamani VN; O'Leary J; Volsky B; Nyambi P; Burda S; Xu S; Littman DR; Zolla-Pazner S
    J Virol; 1998 Sep; 72(9):6988-96. PubMed ID: 9696790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.
    Shi Y; Brandin E; Vincic E; Jansson M; Blaxhult A; Gyllensten K; Moberg L; Broström C; Fenyö EM; Albert J
    J Gen Virol; 2005 Dec; 86(Pt 12):3385-3396. PubMed ID: 16298986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1.
    Zhang L; He T; Huang Y; Chen Z; Guo Y; Wu S; Kunstman KJ; Brown RC; Phair JP; Neumann AU; Ho DD; Wolinsky SM
    J Virol; 1998 Nov; 72(11):9307-12. PubMed ID: 9765480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and use of human immunodeficiency virus type 1 coreceptors by human alveolar macrophages.
    Worgall S; Connor R; Kaner RJ; Fenamore E; Sheridan K; Singh R; Crystal RG
    J Virol; 1999 Jul; 73(7):5865-74. PubMed ID: 10364338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in CCR5 and CXCR4 expression and beta-chemokine production in HIV-1-infected patients treated with highly active antiretroviral therapy.
    Pierdominici M; Giovannetti A; Ensoli F; Mazzetta F; Marziali M; De Cristofaro MR; Santini-Muratori D; Leti W; Aiuti F
    J Acquir Immune Defic Syndr; 2002 Feb; 29(2):122-31. PubMed ID: 11832680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells.
    Willey SJ; Reeves JD; Hudson R; Miyake K; Dejucq N; Schols D; De Clercq E; Bell J; McKnight A; Clapham PR
    J Virol; 2003 Jun; 77(11):6138-52. PubMed ID: 12743271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals.
    Beddows S; Lister S; Cheingsong R; Bruck C; Weber J
    J Virol; 1999 Feb; 73(2):1740-5. PubMed ID: 9882391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of neutralization sensitivity of HIV-1 primary isolates with biological properties of isolates from HIV-1 infected Chinese individuals.
    Hei FX; Tang HL; Hong KX; Chen JP; Peng H; Yuan L; Xu JQ; Shao YM
    Biomed Environ Sci; 2005 Apr; 18(2):128-36. PubMed ID: 16001833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.
    Beaumont T; Broersen S; van Nuenen A; Huisman HG; de Roda Husman AM; Heeney JL; Schuitemaker H
    J Virol; 2000 Sep; 74(17):7699-707. PubMed ID: 10933675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR5 or CXCR4 is required for efficient infection of peripheral blood mononuclear cells by promiscuous human immunodeficiency virus type 2 primary isolates.
    Mörner A; Björndal A; Leandersson AC; Albert J; Björling E; Jansson M
    AIDS Res Hum Retroviruses; 2002 Feb; 18(3):193-200. PubMed ID: 11839153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCR5 and CXCR4 chemokine receptor expression and beta-chemokine production during early T cell repopulation induced by highly active anti-retroviral therapy.
    Giovannetti A; Ensoli F; Mazzetta F; De Cristofaro M; Pierdominici M; Muratori DS; Fiorelli V; Aiuti F
    Clin Exp Immunol; 1999 Oct; 118(1):87-94. PubMed ID: 10540164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.